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Abstract: 
Metabolite analysis of peritoneal dialysis (PD) effluent may provide information regarding onset 
and progression of complications associated with prolonged PD therapy. In this context, the NMR 
detectable small metabolites of PD effluent samples were characterized using high resolution 1H and 1H-
13C NMR spectroscopy. The various spectra were recorded (at 800 MHz proton frequency) on PD 
effluent samples obtained after 4 hour (intraperitoneal) dwell time from patients with end stage renal 
failure (ESRF) and continuing normally on PD therapy. Inspite of devastating spectral feature of PD 
effluent due to the presence of intense resonances from glucose and lactate, we were able to identify 
about 53 small endogenous metabolites (including many complex coupled spin systems) and more than 
90 % of the total CH cross peaks of 1H-13C HSQC spectrum were identified specific to various 
metabolites of PD effluent. We foresee that the characteristic fingerprints of various metabolites of 
control PD effluent samples will be used to identify and distinguish metabolic differences from PD 
related complications. 
 
 
 
  
  
Introduction: 
Peritoneal dialysis (PD) is used for treating patients with end-stage renal failure (ESRF). Though, 
PD gives more freedom compared to haemodialysis, it is often associated with a number of 
complications which could be either immediate or delayed [1-8]. These have broadly been classified into 
two categories based on their aetiologies: (a) infectious including bacterial, tuberculous, fungal, and 
infections of the catheter exit site and tunnel and (b) non-infectious including catheter failure, 
peritoneum damage (caused by PD fluids rendering it unsuitable for adequate dialysis), hernias and 
encapsulating peritoneal sclerosis (EPS, a rare but serious complication) [2-4]. If not diagnosed and 
treated at an early stage, these clinical complications can lead to permanent malfunctioning of peritoneal 
membrane -the condition commonly referred to as peritonitis- which is probably the most common 
cause of morbidity in patients treated with this modality. It is also the major cause of technique failure 
and transfer of patients to haemodialysis (HD), either temporarily or permanently [5,6]. As the number 
of ESRF patients continuing on PD therapy is increasing every year and generally they remain on PD for 
more than 2-5 years [7], the peritonitis episodes are becoming more and more evident. Therefore, an 
efficient method for rapid and early detection of PD-related complications and subsequent recovery is 
needed [5,6].  
For such a purpose, it appears valuable to analyse the PD effluent in a rapid and non-invasive 
manner. Further, the quantitative biochemical information on PD effluent evaluated over a period of 
time during the start of the therapy can be used to assess the success of PD therapy and functionality of 
peritoneal membrane. NMR spectroscopy is ideally suited for identifying biochemical changes [9-15]. 
Particular advantage of NMR is that it gives qualitative and quantitative information about the 
endogenous metabolites. The quantitative measurements of major NMR signals are used to detect 
metabolic up-regulations/down-regulations. Other advantage of NMR is that it requires little or no 
sample preparation and usually a metabolite concentration of greater than a few M is detectable in 1H 
NMR spectra in a reasonable amount of time (1H NMR; 128 scans; approximately 15 min) [10], 
therefore, it provides a better non-invasive predictive measure along with the benefit of rapidity in 
diagnosis.  
So far, no NMR based study on PD effluent seems to have been reported in the context of 
predicting complications associated with prolonged PD therapy. This prompted us to explore the utility 
of NMR spectroscopy in the diagnosis and prognosis PD related complications. Like any other body 
fluid (e.g. urine, serum, bile, synovial fluid, cerebrospinal fluid etc.), PD effluent is a complex mixture of 
hundreds of small metabolites. In order to derive any reliable and meaningful clinical information from 
metabolome analysis of PD effluent, the very first and essential requirement is to identify and assign as 
many metabolites as possible. However, the 1H NMR based analysis of a complex mixture like PD 
effluent is severely hampered by spectral complexity and signal overlap. In case of PD effluent, the 
spectral quality is further impaired by the presence of intense resonances from unused Glucose and 
Lactate (the major constituents of PD fluid). In order to overcome the spectral complexity and 
congestion, we used high field instrument along with two-dimensional (2D) J-resolved (JRES), 
homoneuclear 1H-1H TOCSY (total correlation spectroscopy) and hetroneuclear 1H-13C HSQC 
(heteronuclear single quantum correlation) spectra in combination with 1D 1H NMR spectrum [16-19]. 
Once the metabolites are identified and their 1H and 13C NMR signals are assigned, the data provide 
useful baseline information to assess the feasibility of NMR for clinical studies.  
 
 
 
  
Materials and Method: 
 
Collection of PD Effluent Samples:  
The PD effluent samples (12 episodes) used in this study were obtained from 8 PD patients 
(n=8) admitted in the Nephrology wards of Sanjay Gandhi Post Graduate Institute of Medical Sciences, 
Lucknow. The study protocol was approved by the Hospital's Research Committee. All selected PD 
patients involved in this study (n=8) were continuing normally on the PD therapy (as confirmed 
according to the guidelines of International Society of Peritoneal Dialysis) [5,6]. The main exclusion 
criterion was the presence of infectious disease and cloudy effluent with turbidity. All were instilled (into 
their peritoneal cavity) with PD solutions containing dextrose (2.5 %, Dianeal, Baxter Healthcare). In 
each case, PD effluent sample was collected after a 4 hour dwell time, and was frozen and stored at a 
temperature of -80 C, within 1-2 hours (to preserve the metabolic snapshot in the most optimal way [9]) 
until the NMR measurements were performed. Prior to NMR data collection, all samples were thawed 
and centrifuged to remove precipitates. For 1H NMR experiments 400 µl of supernatant was taken in 5 
mm NMR tubes (Wilmad Glass, USA). A capillary tube containing the known concentration of 0.5% 
TSP (Sodium salt of 3-trimethylsilyl-(2,2,3,3-d4)-propionic acid) in deuterium oxide (D2O) was inserted 
separately in all the NMR tubes both for the purpose of locking and to aid metabolite quantification.  
Deuterium oxide (D2O) and sodium salt of trimethylsilylpropionic acid-d4 (TSP) used for NMR 
spectroscopy were purchased from Sigma-Aldrich (Rhode Island, USA). For evaluating the metabolic 
differences, the control human urine and serum samples were obtained from healthy adult individuals 
and were frozen and stored at a temperature of -80 C, within 1-2 hours until the NMR measurements 
were performed. 
 
NMR Spectroscopy and Assignment: 
All NMR spectra were recorded at 298 K on Bruker Avance III 800 MHz NMR spectrometer 
(equipped with Cryoprobe) using the Bruker’s standard pulse program library. One‐dimensional 1H‐
NMR spectra were recorded on all the available PD effluent samples using the Carr–Purcell–Meiboom–
Gill (CPMG) pulse sequence (cpmgpr1d) with pre-saturation of the water peak [13]. Each spectrum 
consisted of the accumulation of 128 scans with a recycle delay (RD) of 5 sec and lasted for 
approximately 15 minutes. To remove broad signals from triglycerides, proteins, cholesterols and 
phospholipids, a total spin–spin relaxation time of 160 ms (n=400 and 2τ=400 s) was used which 
allowed a better detection of 1H NMR signals from small-molecule metabolites (molecular weight < 1 
kDa). To compare the lipid content of PD effluent with that of human serum and urine, 1D diffusion 
edited 1H NMR spectra were also recorded using the bipolar pulse longitudinal eddy current delay 
(BPPLED) pulse sequence [20]. The square gradients of 70% of the maximum gradient strength (56 
G/cm) and 2 ms duration (followed by a delay of 200 s to allow for the decay of eddy currents) were 
used. Diffusion time of 120 ms was used to attenuate the signals from low molecular weight compounds 
without affecting the lipid signals. All the spectra or FIDs (free induction decays) were processed in 
Topspin-2.1 (Bruker NMR data Processing Software) using standard Fourier Transformation (FT) 
procedure following manual phase and baseline-correction. Prior to FT, each FID was zero-filled to 
4096 data points and a sine–bell apodisation function was applied. After FT, the chemical shifts were 
referenced externally to TSP methyl protons at 0.0 ppm. 
For unambiguous assignment of various metabolite peaks, two-dimensional (2D) homonuclear 
and heteronuclear spectra were recorded on three-to-four effluent samples (selected based on spectral 
heterogeneity to include all the possible metabolites of PD effluent). The details of various NMR 
parameters of these 2D homonuclear and heteronuclear experiments are given in the supporting 
information (Appendix I). Chemical shifts were identified and assigned as far as possible, by 
comparison with the chemical shifts given by the freely available softwares (MetaboMiner [21] and 
MetabolD [22]) and using the data available in literature [23-26] with tolerances of 0.02 ppm (1H) and 
0.5 ppm (13C). Identification was achieved if there was only one candidate in the database within the 
specified tolerances for an observed peak and its correlated shifts.  
 
  
Results and Discussion:  
 
Comparison with Human Urine and Serum: 
Figure 1 shows the representative 1H NMR spectra of control PD effluent stacked up with that 
of human serum and urine obtained from normal healthy individuals. The standard 1D 1H NMR spectra 
of these body fluids with and without T2 (CPMG) relaxation editing are also shown in Supplementary 
Material (Figure S1-S3). The comparison clearly indicates that the 1H NMR spectrum of PD effluent is 
different than that of human urine/serum owing to both (a) different biochemical/metabolic 
composition compared to human serum/urine and (b) chemical shift variation due to different solvent 
properties (especially the bulk diamagnetic susceptibility). However among all, PD effluent is found to 
share proximate composition with urine; apparently because it also contains metabolites consumed from 
and secreted into the intraperitoneal dialysis fluid from the tissue or cells in close proximity [7,27]. Like 
urine, the 1D 1H NMR spectrum of PD effluent (a) contains a strong signal from urea along with an 
increase in the intensity of the underlying broad signals in the aromatic and amide regions (see Figures 
S1-S3 of ESM) and (b) lacks broad signals from fatty acyl chains, proteins and other macromolecules 
which are characteristic features of serum sample (inferred by the diffusion edited 1H NMR spectra of 
these body-fluids as shown in Figure S4 of ESM). Like urine, the 1H NMR spectra of PD effluent 
samples also show a small degree of inter-spectral variation because the natural variability in composition 
of these samples obtained from different PD patients (see Figure S5A of ESM) [28]. These spectral 
variations, if not handled/managed properly during the analysis, can produce faulty results. The other 
devastating feature of effluent 1H NMR spectra is that it contains prominent signals from unused 
constituents -Glucose and Lactate- of PD fluid (see Figure 1A and Figure S5B of ESM). The presence 
of Glucose and Lactate is common in serum samples as well. However, unlike serum which normally 
contains Glucose ranging from 50 to 100 milligram per decilitre (mg/dL), the PD effluent may contain 
unused Glucose between 200 to 1000 mg/dL (the concentration varies from effluent to effluent 
depending upon its intra-peritoneal usage). Such higher concentrations of Glucose produce strong 
signals in the mid frequency region ranging from 3.2 to 4.0 ppm which surmount the signals from other 
metabolites falling in this mid frequency region. In view of this limitation, we have mainly analysed the 
NMR spectra of PD effluent in the low frequency region 0-3.1 ppm and high frequency region 5.5-9.5 
ppm, whereas, the mid frequency region from 3.2-4.0 ppm (predominated by Glucose resonances) has 
been excluded from the analysis.  
 Fig. 1. The typical one-dimensional CPMG 1H NMR spectra of (A) PD effluent, (B) normal human urine, and 
(C) normal human serum, highlighting the difference in metabolic composition and spectral complexity exhibited 
by these body fluids. 
 
Spectral Assignment: 
Prior to resonance assignments all the spectra’s were referenced with respect to the methyl (CH3) 
group of TSP at 0 ppm both for 1H and 13C chemical shift axis. Figure 2 shows the representative 
fingerprint one-dimensional 1H CPMG NMR spectrum of a PD effluent sample. The severe spectral 
congestion and signal overlap in the CPMG 1H NMR spectrum and the perturbed chemical shift values 
due to different solvent properties, altogether pose a challenge in the assignment of 1H chemical shifts 
through the examination of their reported values in the literature. Only few resonances are readily 
assignable by direct inspection of 1D spectrum. The expansions of one-dimensional CPMG 1H NMR 
spectrum of PD effluent in the frequency regions 0.7–1.95 ppm, 1.95–3.21 ppm and 5.6-8.5 ppm are 
shown in Figures 2a, 2b and 2c, respectively. At about 0.83 ppm a sharp doublet due to γ-CH3 moiety 
of 2-hydroxy-3-methylbutyric acid was observed which was followed by triplet due to CH3 group of 2-
hydroxybutyric acid at 0.90 ppm. A doublet due to γ-CH3 group of valine was observed at about 0.99 
ppm followed by two doublets due to δ-CH3 group of isoleucine and γ-CH3 groups of valine at 1.01 and 
1.04 ppm, respectively. A triplet due to CH3 group of ethanol was observed at 1.18 ppm which is slightly 
overlapped with a doublet due to γ-CH3 moiety of 3-Hydroxybutyric acid at 1.20 ppm. A large intensity 
doublet was observed at 1.33 ppm due to CH3 group of lactate followed by a doublet due to methyl  
 Figure 2. The spectral regions: (A) from 0.7–1.95 ppm, (B) from 1.95–3.21 ppm and (C) from 5.6-8.5 ppm- of a 
one-dimensional CPMG 1H NMR spectrum of a PD effluent selected as a typical example for showing the 
assignments of small molecule metabolites (as given in Table S1): 1), 1, 2-propanediol; 2), 2-Hydroxy-3-
methylbutyric acid; 3), 2-Hydroxybutyric acid; 4), 2-oxoglutarate; 5), 3-Hydroxybutyric acid; 6), Acetic acid; 7), 
Acetoacetate; 8), Acetone; 9), Adipic acid; 10), Alanine; 11), Arginine; 12), Asparagine; 13), Carnitine; 14), Citric 
acid; 15), Creatinine; 16), Dimethylamine; 17), Dimethylglycine; 18), Ethanol; 19), Formic acid; 20), Fumaric acid; 
21), α-Glucose; 22), β-Glucose; 23), Glutamate; 24), Glutamine; 25), Choline; 26), Glycine; 27), Guanine; 28), 
Guanosine; 29), Hippurate; 30), Histidine; 31), Isoleucine; 32), Ketoleucine; 33), Lactate; 34), Leucine; 35), Lipids; 
36), Lysine; 37), Methionine; 38), Methylguanidine; 39), Myo-Inositol; 40), N-Acetylglycoproteins; 41), Oxalacetic 
acid; 42), Phenylalanine; 43), Proline; 44), Quinolinic acid; 45), Succinic acid; 46), Taurine; 47), Threonine; 48), 
Trigonelline; 49), Trimethylamine-N-oxide; 50), Tyramine; 51), Tyrosine; 52), Urea; 53), Valine; 54), Unknown 
(U1); 55), Unknown (U2) ; 56), Unknown (U3) ; 57), Unknown (U4) 
 
 
group of alanine at 1.47 ppm. Similarly singlets due to methyl group of acetic acid and CH2 group of 
oxalacetic acid were observed at 1.92 and 2.37 ppm, respectively. Severe spectral congestion and signal 
overlap was seen in the regions, 1.6-1.92 ppm, 1.97-2.15 ppm, 2.29-2.47 ppm and 2.99-3.03 ppm due to 
complex multiplet overlapped by resonances from other metabolites which were assigned using TOCSY 
and HSQC spectra. The methyl groups of acetone and acetoacetate produce singlets at 2.23 and 2.28 
ppm, respectively. Two doublets due to CH2 groups of citric acid were observed at 2.52 and 2.69 ppm 
followed by a singlet at 2.73 ppm due to methyl group of dimethylamine. A singlet due to CH3 group of 
creatinine was also observed at 3.04 ppm. In the high frequency region, we see a broad singlet at 5.78 
ppm due to NH2 group of urea. Two doublets due to C2H & C6H rings of tyrosine and tyramine were 
observed at 6.86 and 6.89 ppm, respectively, followed by a singlet at 7.05 ppm due to C4H-ring of 
histidine. A singlet at 7.77 ppm due to C2H-ring of histidine followed by a doublet at 7.83 ppm due to o-
CH group of hippurate and a singlet at 8.45 ppm due to CH group of formic acid was observed. 
In order to achieve detailed spectral assignment in the complex and highly overlapped regions, 
the information provided by 1D CPMG spectra was combined with 2D J-resolved (JRES), 1H-1H 
TOCSY and 1H-13C HSQC NMR spectra and compared with the libraries of 1H and 13C chemical shifts 
given by the freely available MetaboMiner software [21] and reported in the literature for compounds 
commonly found in biofluids like serum, urine, bile etc. [23-26,29-33]. Overall, fifty three metabolites 
were identified and assigned on the comparison of their existing chemical shifts, cross peak correlations, 
coupling constant and splitting pattern with those of commonly found in biofluids. The assignments of 
resonances are partially shown in the 2D 1H–13C HSQC and 2D 1H–1H TOCSY spectral expansions 
presented in Figure 3 and Figures S6-S7, respectively. The splitting pattern of metabolites has been 
shown in the 2D JRES spectral expansions presented in Figures S8 and S9, respectively. We see that 
spectral congestion regions were well resolved in the two dimensional TOCSY and HSQC spectra. 2D 
HSQC spectra of PD effluent provided much better resolution of metabolites due to more dispersion of 
chemical shift in 13C dimension. Therefore using this advantage of the large spread of 13C chemical shift, 
we were successful in assigning large number of metabolites in the severely overlapped regions, which 
was not possible in the one dimensional plot. Likewise, 1H-1H TOCSY spectrum provided identification 
of many coupled spin systems otherwise overlapped in the 1D experiment for their unambiguous 
assignment. The comprehensive list of all the NMR detectable low MW metabolites of PD effluent, their 
1H chemical shifts (and 13C chemical shifts where available) along with their spin systems and spin 
multiplicities is given in Table S1. Some observed chemical shifts differ from expected database values, 
probably due to a difference in bulk diamagnetic susceptibility. Overall, a significant similarity was found 
in the metabolic composition of PD effluent and that of human urine.  
  
 Figure 3. 2D 1H–13C HSQC spectra of PD effluent. The labelled assignments of the metabolites are as per Table 
S1. As evident, the HSQC spectrum exploits the generally good dispersion of 13C chemical shifts on one axis of 
the 2D spectrum, thus provides increased resolution and greater specificity for unambiguous resonance 
assignment of metabolites. 
 
 
Concluding Remarks:  
This study reports the characterization of metabolites in PD effluent using high-resolution 
1D/2D NMR spectroscopy. We foresee that the spectral fingerprints established here for various 
metabolites of PD effluent may be used for detecting/predicting the complications associated with 
prolonged peritoneal dialysis through identifying and differentiating metabolic differences between 
normal and affected PD effluent samples. Such studies are in progress.  
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Figure S1. Stack plot of representative one-dimensional 1H NMR spectrum of PD effluent samples obtained 
after 4 hour dwell time from PD patients continuing normally on PD therapy: (A) standard spectrum (zgesgp 
from Bruker library with water suppression using excitation sculpting with gradients) and (B) CPMG spin-echo 
spectrum (cpmgpr1d from Bruker library with T2 filter using Carr-Purcell-Meiboom-Gill sequence and water 
suppression using presaturation). Like urine, the 1D 1H NMR spectra of PD effluent showed sharp (narrow line-
widths and adequate signal-to-noise ratios) peaks of low molecular weight metabolites with well-resolved spin–
spin multiplicities. As evident from standard 1D 1H NMR spectra (A), these peaks are superimposed on broader 
signals arising mainly from proteins and phospholipids. 
  
 
 
Figure S2. Stack plot of representative one-dimensional 1H NMR spectrum of control human urine samples: (A) 
standard spectrum (zgesgp from Bruker library with water suppression using F1 presaturation) and (B) CPMG 
spin-echo spectrum (cpmgpr1d from Bruker library with T2 filter using Carr-Purcell-Meiboom-Gill sequence and 
water suppression using F1 presaturation).  
  
 Figure S3. Stack plot of representative one-dimensional 1H NMR spectrum of control human serum samples: 
(A) standard spectrum (zgpr from Bruker library with water suppression using F1 presaturation) and (B) CPMG 
spin-echo spectrum (cpmgpr1d from Bruker library with T2 filter using Carr-Purcell-Meiboom-Gill sequence and 
water suppression using F1 presaturation).  
 Figure S4. Stack plot of representative one-dimensional diffusion-edited 1H NMR spectra of (A) PD effluent, 
(B) normal human urine, and (C) normal human serum, highlighting the difference in signals from fatty acyl 
chains, proteins and other macromolecules.   
  
  
Figure S5A. Stack plot of representative one-dimensional 1H NMR spectrum of PD effluent samples obtained 
after 4 hour dwell time obtained from PD patients continuing normally on PD therapy. The comparison clearly 
shows some inter-spectral variations both in terms of number and position of chemical shifts.  
 
Figure S5B: Stack plot of representative one-dimensional 1H NMR spectrum of PD effluent samples obtained 
after 4 hour dwell time from PD patients continuing normally on PD therapy. As evident, the Glucose and lactate 
resonances are predominant in the region 3.2-4.0 ppm rendering difficult spectral analysis in this region. 
Appendix I: 
 For assignment of 1H and 13C NMR signals from various metabolites, two-dimensional J-resolved 
(JRES), COSY (proton-proton correlation spectroscopy), TOCSY (total proton-proton correlation 
spectroscopy), and 1H-13C HSQC (heteronuclear single quantum coherence) spectra were acquired using 
the Bruker’s standard pulse program library. Homonuclear 2D J-resolved spectra (jresgpprqf) were 
recorded with water pre-saturation during recycle delay (RD) of 2 sec [32]. 16K data points were 
collected along direct proton (F2) dimension with spectral width of 16 ppm, whereas, along indirect J- 
Couplings (F1) dimension, 80 points (increments) corresponding to spectral width of 78 Hz (~0.0976 
ppm) were collected and for each F1 increment, 16 transients were acquired. Prior to Fourier transform, 
free induction decay (FID) signals –acquired in the magnitude mode using quadrature phase (QF)- were 
weighted in both dimensions by a sine-bell function and zero-filled in the F1 dimension to 256 data 
points. The spectra were tilted by 45 to provide orthogonality of the chemical shift and coupling 
constant axes and subsequently symmetrized about the F1 axis. 
  Two-dimensional COSY (cosygpprqf) and TOCSY (dipsi2esgpph) proton-proton correlation 
spectra were acquired, respectively, in magnitude and phase sensitive mode using time proportional 
phase incrementation (TPPI). In each case, 2048 data points along direct dimension (F2) and 512 
increments along indirect dimension (F1) were acquired with 16 transients per increment and a spectral 
width of 12 ppm in both dimensions. The FIDs were weighted using a sine–bell-squared function in 
both dimensions and zero filled to 2048 and 4096 data points, respectively, in the F1 and F2 dimensions 
prior to FT. For COSY experiment, the RD between successive pulse sequence cycles was 1.5 sec, while 
for TOCSY experiment (with mixing time of 80 ms), the RD between successive pulse cycles was 3.0 
sec. Spin-lock was achieved by a DIPSI2 pulse sequence train [33] during the TOCSY mixing time. 
 
Two-dimensional 1H–13C phase sensitive (echo/antiecho) HSQC spectra (hsqcetgp) were 
recorded with inverse detection and 13C decoupling during acquisition using GARP-1 [33]. A RD of 2.0 
sec was used between successive pulse sequence cycles and a refocusing delay equal to 1/(4*1JC–H =1.75 
ms) was employed. 2048 data points with 64 scans per increment and 256 increments were acquired with 
spectral widths of 12 and 165 ppm in the 1H and 13C dimensions, respectively. The FIDs were weighted 
using a sine–bell-squared function in both dimensions and zero filled to 1024 and 2048 data points, 
respectively, in the F1 and F2 dimensions prior to FT. After FT, the final spectrum was manually phase 
corrected and referenced to TSP methyl protons and carbon at 0 ppm in the 1H and 13C dimensions, 
respectively.  
 Figure S6. A typical 2D 1H–1H TOCSY spectrum of PD effluent in the low frequency region from 0.0 to 3.1 
ppm (fitted with standard CPMG 1H NMR sub-spectra on its sides). The labels for the cross-peaks represent the 
metabolite as per the assignment listed in Table S1. 
 
 
 Figure S7. 2D 1H–1H TOCSY spectrum of PD effluent in the high frequency region 5.8-9.2 pap (fitted with 
standard CPMG 1H NMR sub-spectra on its sides). The labels for the cross-peaks represent the metabolite as per 
the assignment listed in Table S1.  
 
 
  
 Figure S8. 2D J-resolved spectrum of PD effluent in the regions (A) 0.8-1.6 ppm and (B) 1.6-2.4 ppm. The 
labelled assignments of the metabolites are as per Table S1. 
 
Figure S9. 2D J-resolved spectrum of PD effluent in the regions (A) 2.4-3.2 ppm and (B) 6.5-8.5 ppm. The 
labelled assignments of the metabolites are as per Table S1. 
 Table S1. 1H chemical shift assignments of the metabolites observed in the NMR spectra of peritoneal dialysis effluent  
using one dimensional (1D) CPMG, two dimensional TOCSY, HSQC, J-resolved spectra and comparing standard NMR 
spectrum of individual metabolites taken from Biological Magnetic Resonance Bank (BMRB) 
S. No. Name of metabolites Assignment δ1H (multiplicity) δ13C Methods 
1 1, 2-propanediol γ-CH3  
½ α-CH2 
½ α-CH2 
β-CH 
1.14 (d) 
3.45 
3.55 
3.89                                                                                                                                                                                                                                                                                                                                               
20.6 
69.1 
69.1 
70.5
1D, TOCSY, HSQC 
2 2-Hydroxy-3-
methylbutyric acid   
γ-CH3 
γ-CH3 
β-CH 
α-CH 
0.83 (d) 
0.97 (d) 
2.03 (m) 
3.85 
18.2 
22.4 
34.2 
 
1D, JRES, TOCSY, HSQC 
3 2-Hydroxybutyric acid 
 
CH3  
½ CH2  
½ CH2  
CH  
0.90 (t) 
1.66 (m) 
1.73 (m) 
4.01 (dd) 
11.3 
29.5 
29.5 
76.8 
1D, JRES, TOCSY, HSQC 
4 2-oxoglutarate γ-CH2 
β-CH2                                                                                                                                                                                                                                                         
2.43 (t) 
3.01 (t) 
33.3 
38.2 
1D, JRES, TOCSY, HSQC 
5 3-Hydroxybutyric acid 
 
γ-CH3  
½ α-CH2 
½ α-CH2 
β-CH 
1.20 (d) 
2.31 (dd) 
2.41 (dd) 
4.16 
24.2 
48.9 
48.9 
68.2 
1D, JRES, TOCSY, HSQC 
6 Acetic acid CH3  1.92 (s) 25.6 1D, JRES, HSQC 
7 Acetoacetic acid CH3  
CH2 
2.28 (s) 
3.45 
31.9 1D, JRES, HSQC 
8 Acetone CH3  2.23 (s) 32.7 1D, JRES, HSQC 
9 Adipic acid CH2 
CH2COOH 
1.56 (m) 
2.19 (m) 
30.2 
38.9 
1D, JRES, TOCSY, HSQC 
10 Alanine β-CH3 
α-CH 
1.48 (d) 
3.78 (q) 
18.8 
53.0 
1D, JRES, TOCSY, HSQC 
11 Arginine γ-CH2 
β-CH2 
δ-CH2 
α-CH 
1.74 (m) 
1.90 (m) 
3.25  
3.76 
27.8 
30.1 
42.9 
58.1 
1D, JRES, TOCSY, HSQC 
12 Asparagine ½ β-CH2 
½ β-CH2 
α-CH 
2.84 (dd) 
2.94 (dd) 
4.00 (dd) 
 1D, JRES, TOCSY 
13 Carnitine α-CH2 
N–(CH3)3 
γ-CH2 
β-CH 
2.43 
3.26 (s) 
3.43  
4.57 
45.4 
50.2 
75.3 
1D, JRES, TOCSY, HSQC 
14 Citric acid ½ γ-CH2 
½ γ-CH2 
2.52 (d) 
2.69 (d) 
47.9 
47.9 
1D, JRES, TOCSY, HSQC 
Table S1 continued      
S. no. Name of metabolites Assignment δ1H (multiplicity) δ13C Methods 
15 Creatinine CH3 
CH2 
3.04 (s) 
4.06 (s) 
32.6 
58.7 
1D, JRES, TOCSY, HSQC 
16 Dimethylamine CH3 2.73 (s) 37.8 1D, HSQC, JRES 
17 Dimethylglycine CH3 
CH2 
2.92 (s) 
3.71 (s) 
46.2 
 
1D,  JRES, HSQC 
18 Ethanol CH3 
CH2 
1.19 (t) 
3.67 (q) 
19.1 1D, TOCSY, JRES,HSQC 
19 Formic acid CH 8.45 (s)  1D, JRES 
20 Fumaric acid CH 6.51 (s)  1D, JRES 
21 α-Glucose C4H 
C2H 
C3H 
½-C6H2 
½-C6H2 
C5H 
C1H 
3.41 (t) 
3.54 (dd) 
3.71 (t) 
3.73 (dd) 
3.77 (dd) 
3.83 (m) 
5.24 (d) 
72.1 
73.9 
75.3 
63.3 
62.9 
73.8 
94.6 
1D, TOCSY, HSQC, JRES 
22 β-Glucose C2H 
C4H 
C5H 
C3H 
½-C6H2 
½-C6H2 
C1H 
3.24 (t) 
3.40 (t) 
3.47 (m) 
3.49 (t) 
3.90 (dd) 
3.84 (m) 
4.65 (d) 
76.6 
72.1 
78.2 
78.2 
63.2 
62.9 
98.4 
1D, TOCSY, HSQC, JRES 
23 Glutamate β-CH2 
γ-CH2 
α-CH 
2.11 (m) 
2.34 (m) 
3.76 
29.8 
35.9 
 
1D, JRES, TOCSY, HSQC 
24 Glutamine β-CH2 
γ-CH2 
α-CH 
2.12 (m) 
2.44 (m) 
3.77  
28.9 
33.3 
56.8 
1D, JRES, TOCSY, HSQC 
25 Choline N–(CH3)3 3.21 (s) 56.4 1D, JRES, TOCSY, HSQC 
26 Glycine α-CH2 3.56 (s) 44.0 1D, TOCSY, HSQC, JRES 
27 Guanine CH 7.68 (s)  1D, TOCSY, JRES 
28 Guanosine ½-CH2 
½-CH2 
C5H 
C4H 
C2H 
C7H 
3.82 
3.90  
4.16 (m) 
4.30 (t) 
5.86 (d) 
7.91 (s) 
 1D, TOCSY, JRES 
29 Hippurate 
 
CH2 
m-CH 
p-CH 
o-CH 
3.98 (d) 
7.55  
7.62  
7.83 (dd) 
 
 
46.3 
 
1D, JRES, TOCSY, HSQC 
Table S1 continued 
S. no. Name of metabolites Assignment δ1H (multiplicity) δ13C Methods 
30 Histidine ½ CH2 
½ CH2 
α-CH 
C4H-ring 
C2H-ring 
3.11 (dd) 
3.23 
3.97 (dd) 
7.05 (s) 
7.77 (s)  
27.4 
27.4 
57.2 
1D, JRES, TOCSY, HSQC 
31 Isoleucine γ-CH3 
δ-CH3 
½ γ-CH2 
½ γ-CH2 
β-CH 
α-CH 
0.93 (t) 
1.01 (d) 
1.25  
1.46  
1.97 
3.67 (d) 
13.6 
17.3 
27.6 
 
 
63.2 
1D, JRES, TOCSY, HSQC 
32 Ketoleucine 2CH3 
CH 
CH2 
0.94 (d) 
2.09 (m) 
2.61(d) 
24.6 
27.2 
51.4 
1D, JRES, TOCSY, HSQC 
33 Lactate β-CH3 
α-CH 
1.33 (d) 
4.11 (q) 
22.6 
70.8 
1D, JRES, TOCSY, HSQC 
34 Leucine δ-CH3 
δ-CH3 
β-CH2 
γ-CH 
α-CH 
0.95 (d) 
0.96 (d) 
1.68 (m) 
1.68 (m) 
3.74 
21.7 
23.2 
26.5 
42.3 
56.1 
1D, JRES, TOCSY, HSQC 
35 Lipids CH3  
(CH2)n 
CH2CH=CH 
CH2CO 
CH=CH-CH2–CH=CH 
CH=CH 
0.87 
1.28 
2.07 
2.27 
2.76 
5.34 
24.8 
32.1 
29.4 
34.1 
 
1D, TOCSY, HSQC 
36 Lysine γ-CH2 
δ-CH2 
β-CH2 
ε-CH2 
α-CH 
1.47 
1.72 (m) 
1.89 (m) 
3.03 (t) 
3.76 (t) 
23.2 
28.9 
32.4 
41.8 
56.7 
1D, JRES, TOCSY, HSQC 
37 Methionine δ-CH3 
β-CH 
γ-CH2 
α-CH 
2.13 (s) 
2.14 (m) 
2.64 (t) 
3.78 
 
 
31.3 
 
1D, JRES, TOCSY, HSQC 
38 Methylguanidine CH3 2.82 (s) 29.8 1D, JRES, HSQC 
39 Myo-Inositol C5H 
C1H & C3H 
C4H & C6H 
C2H 
3.28 
3.53 
3.63 
4.06 (t) 
 
 
 
74.7 
1D, TOCSY, HSQC, JRES 
40 N-Acetylglycoproteins  NHCOCH3 2.04 (s) 24.6 1D, JRES, HSQC 
41 Oxalacetic acid  CH2 2.37 (s) 28.9 1D, JRES, HSQC 
 
Table S1 continued 
S. no. Name of metabolites Assignment δ1H (multiplicity) δ13C Methods 
42 Phenylalanine ½ β-CH2 
½ β-CH2 
C2H & C6H 
C4H 
C3H & C5H 
3.12(dd) 
3.28 (dd) 
7.33 (m) 
7.37 (m) 
7.43 (m) 
38.9 
38.9 
131.5 
129.4 
132.4 
1D, JRES, HSQC 
43 Proline γ-CH2 
½ β-CH2 
½ β-CH2 
½ δ-CH2 
½ δ-CH2 
α-CH 
2.00 (m) 
2.06 (m) 
2.34 (m) 
3.34 
3.41 
4.13 
26.1 
31.8 
31.8 
48.6 
48.6 
63.7 
1D, JRES, TOCSY, HSQC 
44 Quinolinic acid C4H 
C5H 
C6H 
7.46 
8.00 
8.46 
 1D, TOCSY 
45 Succinic acid α, β-CH2 2.41 (s) 36.7 1D, JRES, HSQC 
46 Taurine S-CH2 
N-CH2 
3.26 
3.42 
49.9 
37.9 
1D, JRES, HSQC 
47 Threonine γ-CH3 
α-CH 
β-CH 
1.33 
3.57 (d) 
4.26 (m) 
 
 
66.1 
1D, JRES,  TOCSY, HSQC 
48 Trigonelline CH3 
C4H 
C3H & C5H 
C1H 
4.44 (s) 
8.08 (s) 
8.84 
9.13 
50.6 1D, TOCSY, HSQC, JRES 
49 Trimethylamine-N-
oxide 
N–(CH3)3 3.27 (s) 61.6 1D, JRES,  HSQC 
50 Tyramine CH2 
N–CH2 
C2H & C6H  
C3H & C5H 
2.90 (t) 
3.25 
6.89 (d) 
7.22 (d) 
 
 
118.3 
131.6 
1D, JRES, TOCSY, HSQC 
51 Tyrosine ½ β-CH2 
½ β-CH2 
α-CH 
C2H & C6H 
C3H & C5H 
3.05 (dd) 
3.19 (dd) 
3.93 
6.86 (d) 
7.17 (d) 
37.9 
37.9 
58.4 
118.1 
133.1 
1D, JRES, TOCSY, HSQC 
52 Urea NH2 5.78 (s)  1D, TOCSY 
53 Valine γ-CH3 
γ-CH3 
β-CH  
α-CH 
0.99 (d) 
1.04 (d) 
2.28 (m) 
3.61 
19.2 
20.5 
31.7 
 
1D, JRES, TOCSY, HSQC 
54 Unknown (U1)  1.07 (t) 
2.50 
3.54 
3.71 
 
 
 1D, JRES, TOCSY 
Table S1 continued 
S. no. Name of metabolites Assignment δ1H (multiplicity) δ13C Methods 
55 Unknown (U2)  1.06 (d) 
2.61 
2.87 
 1D, JRES, TOCSY 
56 Unknown (U3)  1.25 (d)  1D, JRES, TOCSY 
57 Unknown (U4)  1.41 (d) 24.6 1D, JRES, TOCSY, HSQC 
(s) Singlet; (d) doublet; (t) triplet; (q) quartet; (dd) doublet of doublets; (m) multiplet. 
 
 
 
